Prescription Drug Abuse (R01)

The summary for the Prescription Drug Abuse (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Prescription Drug Abuse (R01): The National Institute on Drug Abuse (NIDA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.

Federal Grant Title:	Prescription Drug Abuse (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-13-015
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	Jan 07, 2016
Original Application Deadline:	Jan 07, 2016
Posted Date:	Nov 02, 2012
Creation Date:	Nov 02, 2012
Archive Date:	Feb 07, 2016
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/...; • Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clini...; • Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Betwee...; • Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Betwee...; • Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Func...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed); • Coordinating Center to Support Consortium for Neuroscience Alzheimers Disease (AD) and AD-...; • Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials o...; • Administrative Supplements to Promote Diversity in Research and Development Small Business...; • Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R21 Clinical Trial...